CA-II inhibitors can be used to reduce the intraocular pressure usually associated with glaucoma (Supuran and Scozzafava, 2007; Pastorekova and Supuran, 2014; Ruusuvuori and Kaila, 2014; Zaraei et al., 2019). This evidence concerns the gene CA2 and glaucoma.